4 July 2005
Smiths Group announces that Smiths Medical has entered into a cross-licensing agreement with Medtronic MiniMed Inc. The agreement terminates all pending litigation between the companies relating to the Deltec Cozmo ® insulin pump, and confirms that no changes are required to the design of the pump, which is one of a range of innovative products driving the growth of Smiths Medical.
Under the terms of the agreement Smiths will make an initial payment to Medtronic and will pay a royalty on future sales of the current model.
The costs of the settlement will be treated as an exceptional charge in Smiths Group's 2005 Accounts. Subject to audit, this charge is expected to be no more than £15 million. The impact of this settlement on the future profits of Smiths Medical is unlikely to be material.
ENDS
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
Smiths Group supports NASA’s Europa Clipper mission to explore Jupiter’s moon, Europa
Find out more
Smiths Detection awarded service subcontract
Providing preventative and corrective maintenance for 486 hold baggage scanning systems across 41 airports in the United States
Find out more
Smiths Group publishes 2024 ‘Sustainability at Smiths’ report
Smiths Group publishes its latest ‘Sustainability at Smiths’ report for the fiscal year 2024. The report outlines the progress that Smiths Group has made during the year on its ESG agenda.
Find out more
